Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Ju-lun Yang"'
Autor:
Peng Lin, Jing Qian, Cheng-Cheng Huang, Wen-Mang Xu, Yuan-Yuan Wang, Zi-Ran Gao, Shi-Qi Zheng, Peng Wang, Da-Qi Jia, Qiang Feng, Ju-Lun Yang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background Ras gene mutation and/or overexpression are drivers in the progression of cancers, including colorectal cancer. Blocking the Ras signaling has become a significant strategy for cancer therapy. Previously, we constructed a recombin
Externí odkaz:
https://doaj.org/article/a112d3f3792545fc8ef543d47b18007e
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/a65c494f3a9047cbb7c93375bba52ce0
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background We prepared an anti-p21Ras scFv which could specifically bind with mutant and wild-type p21Ras. However, it cannot penetrate the cell membrane, which prevents it from binding to p21Ras in the cytoplasm. Here, the RGD4C peptide was
Externí odkaz:
https://doaj.org/article/3aae4cb884934f73bf6fbbb9a73aa83c
Autor:
Yi-xing Wang, Yuan-yuan Wang, Cheng-gang Yang, Hong Bu, Wen-tao Yang, Li Wang, Wen-mang Xu, Xi-long Zhao, Wen-xing Zhao, Lei Li, Shu-ling Song, Ju-lun Yang
Publikováno v:
Breast, Vol 49, Iss , Pp 225-232 (2020)
Purpose: The proliferation marker Ki67 has prognostic and predictive values in breast cancer, and the cutoff of the Ki67 label index (LI) is a key index for chemotherapy. However, poor interobserver consistency in Ki67 assessment has limited the clin
Externí odkaz:
https://doaj.org/article/418bb0a079864341b2a170645c88f8d3
Autor:
Fang-Rui Liu, Shuang Bai, Qiang Feng, Xin-Yan Pan, Shu-Ling Song, Hong Fang, Jing Cui, Ju-Lun Yang
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Colorectal cancer (CRC) is the most common type of gastrointestinal cancer. CRC gene therapy mediated by adenovirus holds great promise for the treatment of malignancies. However, intravenous delivery of adenovirus exhibits limite
Externí odkaz:
https://doaj.org/article/7e264a4491fc43fab5d1ca87214e6e72
Publikováno v:
Anti-Cancer Drugs
Activatable cell-penetrating peptide (ACPP) is a tumour-targeting cell-penetrating peptide. Here, we used ACPP to carry anti-p21Ras scFv for Ras-driven cancer therapy. The ACPP-p21Ras scFv fusion protein was prepared by a prokaryotic expression syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a185892202030964525b95c34d7890a
https://doi.org/10.1097/cad.0000000000001180
https://doi.org/10.1097/cad.0000000000001180
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
We prepared an anti-p21Ras scFv which could specifically bind with mutant and wild-type p21Ras. However, it cannot penetrate the cell membrane, which prevents it from binding to p21Ras in the cytoplasm. Here, the RGD4C peptide was used to mediate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf1a4c441e35b532147f40aa0137325
https://doaj.org/article/a65c494f3a9047cbb7c93375bba52ce0
https://doaj.org/article/a65c494f3a9047cbb7c93375bba52ce0
Publikováno v:
Journal of Cancer
Background: Oncolytic adenovirus-mediated gene therapy is an emerging strategy for cancer treatment. However, oncolytic adenoviruses are mainly administered locally at tumor site. Intravenous administration of oncolytic adenovirus for cancer gene the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cc9551645b6d0a491d15042e9d1ebe
http://europepmc.org/articles/PMC8040716
http://europepmc.org/articles/PMC8040716
Publikováno v:
Immunotherapy. 12:879-890
Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistoch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4f5940aed2d8aba7e0343e94d6a23c
https://doi.org/10.2217/imt-2019-0222
https://doi.org/10.2217/imt-2019-0222
Publikováno v:
Cancer Biomarkers. 28:293-299
Background/objective CD133 is the molecular marker of normal stem cells and progenitor cells and also confirmed as a marker for cancer stem cells in various tumors. The aim of this study is to examine the expression of CD133 and assess its clinicopat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1382e2e3eea8009480022517fcee53a
https://doi.org/10.3233/cbm-190196
https://doi.org/10.3233/cbm-190196